Sumitomo Pharma America Announces U.S. FDA Approval of GEMTESA® (vibegron ... - Morningstar
Sumitomo Pharma America announces FDA approval of GEMTESA® (vibegron), the first β3 agonist for men with OAB symptoms on pharmacological therapy for BPH, available for prescription in the U.S.
Highlighted Terms
Related News
Sumitomo Pharma America Announces U.S. FDA Approval of GEMTESA® (vibegron ... - Morningstar
Sumitomo Pharma America announces FDA approval of GEMTESA® (vibegron), the first β3 agonist for men with OAB symptoms on pharmacological therapy for BPH, available for prescription in the U.S.